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Abstract
In this study, we investigate the association between computed tomography-based radiomic features and
epidermal growth factor receptor (EGFR) mutation status in 298 patients with surgically resected peripheral
lung adenocarcinomas. Eleven radiomic features from 7 different feature categories were signiﬁcantly asso-
ciated with EGFR mutations. Adding radiomic features to a clinical model improved the predictive power of
EGFR mutations.
Background: In this study we retrospectively evaluated the capability of computed tomography (CT)-based radiomic
features to predict epidermal growth factor receptor (EGFR) mutation status in surgically-resected peripheral lung
adenocarcinomas in an Asian cohort of patients. Patients and Methods: Two hundred ninety-eight patients with
surgically resected peripheral lung adenocarcinomas were investigated in this institutional review board-approved
retrospective study with requirement waived to obtain informed consent. Two hundred nineteen quantitative 3-D
features were extracted from segmented volumes of each tumor, and 59 of these, which were considered indepen-
dent features, were included in the analysis. Clinical and pathological information was obtained from the institutional
database. Results: Mutant EGFR was signiﬁcantly associated with female sex (P ¼ .0005); never smoker status (P <
.0001), lepidic predominant adenocarcinomas (P ¼ .017), and low or intermediate pathologic grade (P ¼ .0002).
Statistically signiﬁcant differences were found in 11 radiomic features between EGFR mutant and wild type groups in
univariate analysis. Mutant EGFR status could be predicted by a set of 5 radiomic features that fell into 3 broad
groups: CT attenuation energy, tumor main direction, and texture deﬁned according to wavelets and Laws (area under
the curve [AUC], 0.647). A multiple logistic regression model showed that adding radiomic features to a clinical model
resulted in a signiﬁcant improvement of predicting power, because the AUC increased from 0.667 to 0.709 (P < .0001).
Conclusion: Computed tomography-based radiomic features of peripheral lung adenocarcinomas can capture useful
information regarding tumor phenotype, and the model we built can be useful to predict the presence of EGFR mu-
tations in peripheral lung adenocarcinoma in Asian patients when mutational proﬁling is not available or possible.
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Lung cancer accounts for 13% of new cancers diagnosed
worldwide and is the leading cause of cancer-related deaths.1 Of all
lung cancers 85% are nonesmall-cell lung carcinoma (NSCLC),
with adenocarcinoma being the most common histologic subtype.2
Over the past decade, molecular translational research advances have
heralded major breakthroughs in the understanding, diagnosis, and
management of lung cancer, particularly the development of new
target-based therapies directed against key signaling pathways
involved in lung cancer growth and malignant progression.3,4 Small-
molecule tyrosine kinase inhibitors (TKIs) that target the epidermal
growth factor receptor (EGFR) were the ﬁrst targeted drugs to enter
clinical use for the treatment of NSCLC. Patients with EGFRClinical Lung Cancer September 2016 - 441
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than those with EGFR wild type or unknown mutation status
(10%-20%).5 Randomized trials have clearly shown that treatments
with targeted TKIs, such as erlotinib, geﬁtinib, or afatinib are
associated with longer progression-free survival (PFS) and higher
objective radiographic response rates than standard ﬁrst-line
chemotherapy in patients with mutated EGFR lung cancer.6-9
However, if geﬁtinib is administered in the case of non-EGFR
mutated lung cancer, the patient will experience a shorter PFS
compared with platinum-based chemotherapy,3 highlighting the
importance of identifying this genetically unique subset of patients.
Cumulative epidemiology studies have identiﬁed several clinico-
pathological factors such as female, nonsmoker, adenocarcinoma
histology, and East Asian origin that were associated with a high
prevalence of EGFR mutation.10,11 Unfortunately, there are no
reliable clinical characteristics that allow for accurate prediction of
EGFR mutation status. For some patients, biopsy samples might be
the only tumor materials available for testing EGFR mutation status
and they are often composed of variable ratios of tumor to normal
cells.12 Thus, mutant DNA alleles present at extremely low con-
centrations become difﬁcult to detect, leading to a false negative
result. Further, because of intratumoral heterogeneity, the portion
of the tumor tested for EGFR mutation might also result as negative
but might be truly positive.13-15 In a recent study,16 2 sequencing-
based mutation detection approaches (dideoxy and pyrosequencing)
were validated against parallel sequencing in a clinical setting, and
the results showed that dideoxy sequencing missed 4 responders and
pyrosequencing missed 2 responders; meanwhile, precise quantiﬁ-
cation of mutant alleles revealed a low correlation of histopatho-
logical estimates of tumor content and frequency of mutant alleles,
indicating that sequencing technologies with inferior sensitivity
might fail to detect clinically relevant oncogene mutations in cancer
patients. Therefore, when receiving a negative mutation analysis
result, one must consider whether the cell sample was truly repre-
sentative for the EGFR mutation status of the lung tumor.
There have been several reports regarding the relationship between
computed tomography (CT) features and EGFR mutation status in
NSCLC17-20; however, the ﬁndings were not consistent with each
other. According to a study conducted by Zhou et al,18 there were no
differences in morphological CT features between EGFR mutation
and wild type tumors. In contrast, Rizzo et al17 reported that EGFR
mutation was signiﬁcantly associated with air bronchogram, pleural
retraction, small lesion size, and absence of ﬁbrosis. Recent techno-
logical advances in medical imaging allow high-throughput extrac-
tion of quantitative imaging features. Radiomics is the process of
converting images to mineable data through computational ap-
proaches. These data can be used to develop decision support systems
to accurately estimate patient risk and improve individualized treat-
ment.21,22 Several studies have shown that such features extracted
from CT images of lung cancers can be useful to distinguish
radiation-induced ﬁbrosis from tumor recurrence,23 differentiate the
presence of Kirsten rat sarcoma viral oncogene (K-ras) mutation from
pan wild type NSCLC,24 provide an independent predictive indi-
cator of response to ﬁrst-line chemotherapy,25 and identify patients
with locally advanced lung adenocarcinoma at risk of developing
distant metastasis.26 CT imaging is routinely used in lung cancer, and
we thus hypothesize that if CT-based radiomic features associatedClinical Lung Cancer September 2016with EGFR mutation status can be determined, they could provide a
useful clinical predictor in patients with unresectable lung cancer or
those in whom biopsy is unable to be performed. Imaging-based risk
models might also provide additional information for clinicians on
whether rebiopsy is needed for patients with a negative EGFR mu-
tation result. Therefore, in this retrospective study, we performed a
radiomic analysis to identify image biomarkers of harboring the
EGFR mutation in peripheral lung adenocarcinomas in a Chinese
cohort of patients.
Patients and Methods
This retrospective study was approved by the institutional review
board. Requirement for informed consent was waived.
Study Population
A consecutive search of the surgical database at our institution
between December 2012 and March 2014 identiﬁed 397 patients
with primary lung adenocarcinoma who fulﬁlled the following in-
clusion criteria: (1) pathology reports with diagnosis of lung
adenocarcinoma; (2) preoperative thin-section CT images at in the
Picture Archiving and Communication System (PACS), and the
location of the lesion was peripheral (tumor involving subsegmental
bronchus or smaller airway); (3) available test results for EGFR
mutation status; and (4) available clinical data. Thereafter, 99 pa-
tients were excluded because of the following reasons: receiving
preoperative treatment, such as radiotherapy or chemotherapy; the
duration between CT examination and subsequence surgery
exceeded 1 month; and patients with lung cancer for which it is
difﬁcult to contour the tumor margin on CT images.
Clinical and pathological data collected for analysis included sex, age
at diagnosis, smoking status, pathologic tumor, node,metastases stage,
and histologic lung adenocarcinoma subtypes. Smoking status was
categorized into 2 groups; never smokers and smokers, which included
former and current smokers. Tumors were staged pathologically ac-
cording to the seventh edition of the American Joint Committee on
Cancer StagingManual.27 Tumorswere diagnosed as adenocarcinoma
and then categorized according to the 2011 International Association
for the Study of Lung Cancer, American Thoracic Society, and
European Respiratory Society classiﬁcation system.28
Computed Tomography Examination
Chest CT examinations were conducted using Somatom Sensa-
tion 64 (Siemens Medical Solutions, Forchheim, Germany), Light
speed 16 (GE Medical Systems, Milwaukee, WI), or Discovery
CT750 HD scanner (GE Medical Systems). The parameters used
were as follows: 120 kVp with tube current adjusted automatically,
pitch was 0.969, reconstruction thickness was 1.5 mm, and
reconstruction interval was 1.5 mm for the 64-detector scanner;
tube voltage was 120 kVp, tube current was 150 to 200 mA, pitch
was 0.969; reconstruction thickness was 1.25 mm, and recon-
struction interval was 1.25 mm for the 16-detector scanner and
Discovery CT750 HD scanner (GE Medical Systems).
Detection of EGFR Mutations
For the gene mutation analysis, tumor specimens were obtained
using surgical resection. We performed EGFR mutation analyses of
4 tyrosine kinase domain (exons 18-21), which are frequently
Ying Liu et almutated in lung cancer, as previously described.29 EGFR mutations
were determined using an ampliﬁcation refractory mutation system
real-time technology using Human EGFR Gene Mutations
Detection Kit (Beijing ACCB Biotech Ltd).
Tumor Segmentation
We used Deﬁniens Developer XD (Munich, Germany) as the
image analysis platform to perform tumor segmentation and feature
extraction. A lung tumor analysis tool within Deﬁniens Cognition
Network Technology was used. Lesions were volumetrically
segmented using a semiautomatic approach by 2 radiologists with
more than 6 and 3 years of experience in CT imaging of thoracic
malignancies, respectively (Figure 1). The semiautomatic segmen-
tation work ﬂow which contained the following 4 steps named
preprocessing, semiautomated correction of the pulmonary
boundary, click and grow, and manual reﬁnement and generation of
lesion statistics were described in detail in previous studies.30-32Figure 1 Representative Computed Tomography Image With Tumor
Adenocarcinoma. (A) A Lobulated Lung Tumor in the Right
Segmented the Boundary of the Tumor, Which Is Shown i
Segmented TumorHere, the single-click ensemble segmentation (SCES) algorithm,31
which is an advanced version of the previous click and grow algo-
rithm and reduces sensitivity toward the location of the initial seed-
point, was used. The SCES makes use of the original algorithm by
choosing different seed points automatically within a speciﬁed area
of the lesion and performing region-growing with each generated
seed point. Each of the 2 radiologists reviewed the segmented im-
ages in consensus, and any discrepancies were resolved by discussion
until consensus was reached.
Radiomic Feature Extraction
We extracted a total of 219 features from each of the 3-D objects.
These features were divided into 8 categories, including tumor size,
shape, location, air space, pixel intensity histogram, run length and
co-occurrence, Laws texture, and wavelets. A description of all
features is provided (Supplemental Table 1 in the online version),
and detailed description of texture features can be found in theSegmentation Using a Semiautomated Algorithm for Peripheral
Middle Lobe Was Chosen for Segmentation. (B) One Radiologist
n Green Outline. (C) Three-Dimensional View of the Lung and
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Table 1 Clinicopathological Characteristics of Patients
Variable
Overall
Data Set
(n [ 298)
EGFR
Mutant
(n [ 137)
EGFR Wild
Type
(n [ 161) P
Median Age (Range) 60 (30-80) 59 (37-80) 60 (30-79) .51
Sex .001
Male 126 43 (31.39) 83 (51.55)
Female 172 94 (68.61) 78 (48.45)
Smoking Status <.0001
Smoker 136 43 (31.39) 93 (57.76)
Never smoker 162 94 (68.61) 68 (42.24)
Pathologic Gradea .0002
High 74 20 (14.60) 54 (33.75)
Low/intermediate 223 117 (85.40) 106 (66.25)
Histologic Subtypeb .022
Lepidic predominant
adenocarcinomas
74 43 (31.39) 31 (19.25)
Other 224 94 (68.61) 130 (80.75)
Stage .53
I or II 208 93 (67.88) 115 (71.43)
III or IV 90 44 (32.12) 46 (28.57)
Data are presented as n, or n (%), except where otherwise noted.
Abbreviation: MIA ¼ minimally invasive adenocarcinoma.
aAdenocarcinoma in situ and MIA were classiﬁed as low grade; lepidic, acinar, and papillary as
intermediate grade; micropapillary, solid, and invasive mucinous adenocarcinoma as high
grade. One case with enteric was eliminated in this analysis.
bHistologic subtype was categorized as lepidic predominant adenocarcinomas (adenocarcinoma
in situ, MIA, and lepidic predominant invasive adenocarcinoma) and other subtypes of dominant
histologic ﬁndings (acinar, papillary, micropapillary, and solid predominant as well as variants of
invasive adenocarcinoma).
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444 -previous study.33 Our features cover a variety of descriptors from
size, location, attachment of the lesion of interest, to CT pixel
distribution and texture according to appearance on CT image. We
characterized texture in observed CT images using the Laws feature
descriptor and in the decomposed domain by using wavelets.
Texture features are known to carry information that are not always
typically observed by the human eye. Metrics were described by
wavelet transformation, and Laws features are considered to describe
subtle characteristics in the image and have been shown to be useful
in image classiﬁcations.34
Statistical Analysis
All statistical analyses was performed using SAS software version
9.4 (SAS Institute Inc, Cary NC). Power transformation was
considered to apply parametric analytical tools. The correlation
between features was investigated to address collinearity issues. The
highly correlated features (correlation > 0.9) were regarded as
dependent features, which were not considered in this analysis.
Thus, 59 of 219 features were considered as mutually independent
features for prediction of EGFR mutation. Fisher exact test and the
KruskaleWallis test were used for categorical and continuous var-
iables between 2 groups, respectively. Multiple logistic regression
analysis was performed. The ﬁnal model was selected using the
backward elimination method. Variables with a P value of < .25 in
the univariate model were entered in the initial model, and then a
variable with a P value of > .15 was eliminated at each step. The
elimination procedure was terminated when the P value of all var-
iables in the model was < .15. The accuracy and error of the pre-
dictive models (ie, the area under the curve [AUC] and 95%
conﬁdence interval [CI]) were estimated using the bootstrap
method with 1000 bootstrap samples. Receiver operating charac-
teristic (ROC) curves for each model were constructed and the
AUC was calculated with EGFR mutation status determined using
an ampliﬁcation refractory mutation system-polymerase chain re-
action (PCR) as outcome. Further, various predictive models were
developed using the support vector machine and principal compo-
nent analysis and were compared with the logistic regression model.
In this study, the regression model was selected as the AUC of the
model that was higher than any other models (results were omitted).
A 2-sided P value of < .05 was regarded as statistically signiﬁcant.
Results
The patient demographic and clinicopathological data are pre-
sented in Table 1. All 298 of the enrolled patients were surgically
treated: lobectomy in 280 patients, pneumonectomy in 4, wedge
resection in 6, and segmentectomy in 8 patients. Overall, there were
126 men and 172 women with a median age of 60 years (range, 30-
80 years). The pathologic stage distribution was as follows: IA in
117 patients (39.26%), IB in 63 patients (21.14%), IIA in 22
patients (7.38%), IIB in 6 patients (2.01%), IIIA in 72 patients
(24.16%), IIIB in 2 patients (0.67%), and IV in 16 patients
(5.37%). Most of the tumors were early stage (stage I or II; 208
[69.80%] of 298). All cases were lung adenocarcinomas and the
most common histologic subtype among invasive adenocarcinomas
was acinar predominant subtype (128 [42.95%] of 298), followed
by lepidic predominant subtype (71 [23.83%] of 298). EGFR
mutation results (Supplemental Table 2 in the online version) wereClinical Lung Cancer September 2016satisfactorily shown in all patents, with 137 patients (45.97%) of
the full cohort of 298 cases identiﬁed as EGFR mutant and 161
(54.03%) as EGFR wild type.
There were signiﬁcant differences in sex, smoking status, path-
ologic grade, and histologic subtype between the EGFR wild type
group and the EGFR mutant group (Table 1). Concerning sex,
there were signiﬁcantly more female patients with mutant,
compared with wild type EGFR in lung adenocarcinomas (odds
ratio [OR], 2.33; 95% CI, 1.45-3.74; P ¼ .001). Smokers with
mutant EGFR were signiﬁcant fewer than smokers with wild type
(OR, 2.99; 95% CI, 1.85-4.82; P < .0001). EGFR mutations were
also signiﬁcantly more frequent in patients with low or intermediate
pathologic grade (OR, 2.98; 95% CI, 1.67-5.30; P ¼ .0002), and
patients with lepidic-predominant adenocarcinomas (OR, 1.92;
95% CI, 1.13-3.27; P ¼ .022). There were no differences in stage
distribution or median age between EGFR mutant and wild type
groups (P ¼ .53; P ¼ .51). Univariate analyses revealed that 4
clinical factors might be associated with EGFR mutation status in
peripheral lung adenocarcinoma: sex, smoking status, histologic
subtype, and pathologic grade were all signiﬁcant predictors of
harboring an EGFR mutation (Table 2).
We then investigated the association of radiomic featureswithEGFR
mutation status. Because this analysis produced far more features that
were considered dependent; only a prioritized subset of features were
selected for further analysis to avoid overﬁtting. Prioritization methods
are described in Locatelli-Sanchez et al.29 Fifty-nine independent
Table 2 Univariate Analysis for Clinicopathological Factors
That Predict Epidermal Growth Factor Receptor
Mutation Status
Clinical Features
Odds Ratio
PPoint
95% CI
Lower Upper
Stage
I or II Reference
III or IV 1.18 0.72 1.94 .51
Sex
Female Reference
Male 0.43 0.27 0.69 .0005
Histologic Subtype
Others Reference
Lepidic predominant
adenocarcinomas
1.92 1.13 3.27 .017
Pathological Grade
Low or intermediate Reference
High 0.34 0.19 0.60 .0002
Smoking Status
Never smoker Reference
Smoker 0.34 0.21 0.54 <.0001
Age (per 5-Year
Increase)
0.97 0.85 1.11 .68
Table 3 Univariate Analysis for Radiomic Features That
Predict Epidermal Growth Factor Receptor Mutation
Status
Radiomic Features
Odds Ratio
PPoint
95% CI
Lower Upper
F19
10a_3D_Relative_
Volume_AirSpaces
1.16 1.04 1.3 .007
F186
Histogram ENERGY
Layer 1
0.49 0.29 0.82 .007
F90
3-D Laws features L5
L5 L5 Layer 1
0.82 0.7 0.96 .015
F51
AvgLRE 0.11 0.02 0.72 .021
F47
AvgCoocurrence-mean 0.98 0.97 1 .025
F190
3-D Wavelet
decomposition. P2 L2
C9 Layer 1
1.26 1.03 1.55 .025
F185
Histogram SD Layer 1 1.88 1.07 3.31 .027
F26
Elliptic Fit 0.11 0.02 0.79 .028
F17
9f-3D-Min-Dist-COG-
to-Border
0.59 0.36 0.96 .032
F111
3-D Laws features R5
E5 R5 Layer 1
0.71 0.51 0.99 .041
F27
Main direction 1.21 1 1.45 .048
Ying Liu et alfeatures were selected ﬁnally (Supplemental Table 3 in the online
version). Among these 59 independent features, 11 were independent
predictors of harboring the EGFR mutation (Table 3, Supplemental
Table 4 in the online version) in univariate analysis, including 1
feature describing tumor shape (F26), 2 features describing tumor
location (F17, F27), 1 feature describing air space (F19), 2 pixel in-
tensity histogram-based features (F185, F186), 2 run length and
coeoccurrence-based features (F47, F51), 2 Laws texture features
(F90, F111), and 1 wavelet texture feature (F190).
With multiple logistic regression analyses, clinical features of
smoking status and pathologic grade proved to be independent
predictors of EGFR mutation, and the AUC of ROC was 0.667
(95% CI, 0.604-0.721). The multiple logistic regression model
produced from radiomic features alone showed moderate predictive
power (AUC, 0.647; 95% CI, 0.576-0.701) for identifying EGFR
mutant status. There was a signiﬁcant difference between AUCs of
the logistic regression model incorporating only clinical features,
and that incorporating only radiomic features (P < .0001). When
clinical and radiomic features were combined, the AUC was
increased to 0.709 (95% CI, 0.654-0.766; Table 4). The model
generated with combined clinical and radiomic features was superior
to the model generated with clinical features alone (P < .0001) and
the model created with radiomic features alone (P < .0001;
Figure 2).
Discussion
There are various methods to detect EGFR mutations, such as
direct sequencing of PCR-ampliﬁed genomic DNA, high-resolution
melting analysis, fragment analysis, restriction fragment lengthpolymorphism, and the ampliﬁcation refractory mutation system35;
however, these molecular methods are generally costly, and some-
times in a low percentage of tumor cells, we would have most likely
missed the mutations and rebiopsy had to be recommended. In this
study, we sought to apply radiomic features to peripheral lung ad-
enocarcinomas to determine if we could noninvasively discriminate
EGFR-mutant from EGFR-wild type cases in a routine practice
without adding additional cost.
We found that 137 of the tumors harbored the EGFR mutation,
which corresponded to 45.97% of the 298 tumor samples, this is in
keeping with previous reports on Asian patients36; in addition, exon
19 and exon 21, the most common mutation types of the EGFR
gene, showed nearly the same percentage in these patients (46.72%
(64/137), 48.91% (67/137), respectively). Dual mutations were
detected in 1 patient (0.73%) in this study, conﬁrming that the
existence of EGFR TKI-resistant (exon 20) and -sensitive mutation
(exon 21) is rare. Several studies indicated that the EGFR mutation
was strongly related with never smokers, female sex, adenocarci-
noma, and pathologic stage.29,36 Consistent with most of theseClinical Lung Cancer September 2016 - 445
Table 4 Multiple Logistic Regression Analysis of Clinicopathological Parameters and Radiomic Features Predicting the Presence of
Epidermal Growth Factor Receptor Mutation in Peripheral Lung Adenocarcinomas
Model Feature P
Odds Ratio AUC
Point
95% CI
Point
95% CI
Lower Upper Lower Upper
Clinical Features Pathologic grade
(ref ¼ lower or
Intermediate)
High .002 0.39 0.22 0.70 0.667 0.604 0.721
Smoking status
(ref ¼ never smoker)
Yes <.0001 0.38 0.23 0.61
Radiomic Feature Main direction (F27) .115 1.17 0.96 1.42 0.647 0.576 0.701
3-D Laws features L5 L5 S5 Layer 1
(F92)
.010 0.52 0.31 0.85
Histogram ENERGY layer 1 (F186) .025 0.50 0.27 0.92
3-D wavelet decomposition.
P2 L2 C9 Layer 1 (F190)
.048 1.29 1.00 1.67
3-D wavelet decomposition.
P1 L2 C5 Layer 1 (F216)
.137 1.16 0.96 1.40
Clinical and
Radiomic Features
Pathologic grade
(ref ¼ lower or
intermediate)
High .016 0.47 0.25 0.87 0.709 0.654 0.766
Smoking status
(ref ¼ never smoker)
Yes .001 0.41 0.25 0.67
Main direction (F27) .20 1.14 0.93 1.40
3-D Laws features L5 L5 S5
layer 1 (F92)
.056 0.60 0.36 1.01
Histogram ENERGY layer 1 (F186) .11 0.60 0.32 1.13
3-D Wavelet decomposition.
P2 L2 C9 Layer 1 (F190)
.13 1.22 0.94 1.59
3-D wavelet decomposition.
P1 L2 C5 Layer 1 (F216)
.24 1.13 0.92 1.38
Abbreviation: AUC ¼ area under the curve.
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446 -ﬁndings, the rate of EGFR mutation in female and never-smoker
patients with lung adenocarcinomas was considerably higher
compared with male and smoker patients in this study. Although
the EGFR mutation was detected more frequently in early-stage
patients (93 [67.88%] of 298) compared with advanced stage (44
[32.12%] of 137), the difference was not signiﬁcant. The results of
the multiple logistic regression analysis revealed that pathologic
grade and smoking status were independent predictors for EGFR
mutation and the AUC was 0.667. Besides clinical information,
more detailed factors will likely be required to identify those at high
probability of harboring EGFR mutations.
Computed tomography imaging is used widely in oncologic
practice for lung tumor characterization. Usually, we interpret the
image on the basis of visual assessment; there are features, however,
within each image that might not be perceived by the naked eye and
require computer-aided techniques. Previous authors have shown the
potential of quantitative CT-based texture analysis in differentiation
of K-ras mutation from pan-wild type NSCLC.24 To the best of our
knowledge, only 1 study37 that was published recently has explored
the association between CT gray-level texture features and EGFR
mutations in a relatively small sample size (25 patients with EGFR
mutation and 20 patients with EGFR wild type). In this study, we
present comprehensive radiomic analysis using semiautomatic seg-
mentation in 298 peripheral lung adenocarcinomas. Two hundredClinical Lung Cancer September 2016nineteen radiomic features were extracted to assess the ability to
predict EGFR mutation status. Considering that using too many
features in the classiﬁcation algorithm can lead to overﬁtting, in which
noise or irrelevant features might exert undue inﬂuence on classiﬁ-
cation decisions, only features that are not associated with other fea-
tures were selected for further analysis. With this approach, we found
that 11 radiomic features from 7 different feature categories were
signiﬁcantly associated with EGFR mutations. Texture features,
wavelet features, Laws features, and along with pixel statistical, have
seen a resurgent use in medical images, especially CT and magnetic
resonance images.24,38 In our study we formed sets of 5 one-
dimensional Laws ﬁlters, each designed to describe different struc-
tures in the image (E: edges, S: spots, R: ripple,W:waves, L: low pass).
The wavelet transformation was limited to 2 levels (L) of decompo-
sition on each of the 9 faces (C) on the 3-D tumor, with 2 types of
metrics (P), namely, energy and entropy. Our statistical model ﬁnds
Laws features L5L5S5 and wavelet P2L2C9 and P1L2C5 to be 1 of
the 5 predictors of EGFR mutation status. Several previous
studies17,39 showed that EGFR mutation was associated with small
tumor size. In our analysis, size-based features including longest
diameter and short axis were not signiﬁcant predictors for the EGFR
mutation. We believe that this difference can be explained in part by
the fact that most clinically assessed tumor diameters are manually
drawn on the central slice of CT images and limited to 1 dimension of
Figure 2 Receiver Operating Characteristic Curves for the
Prediction of Epidermal Growth Factor Receptor
Mutation Using a Logistic Regression Model That
Included Clinical Factors Alone (Green Line), a Model
That Used Radiomic Features Alone (Red Line), and a
Model That Combined Clinical Factors and Radiomic
Features (Blue Line). The Highest Area Under the Curve
(AUC) Was Achieved for the Combination of Clinical
Factors and Radiomic Features (AUC[ 0.709)
Ying Liu et althe tumor, and whole tumor volume was taken into account in the
size-based radiomic features.
With logistic regression analysis, we identiﬁed that radiomic
features could be served as an imaging surrogate for EGFR muta-
tion, although the AUC of radiomic features alone was not as high
as the model created with clinical features, they provide comple-
mentary information, as the combination results in an improved
ROC curve (AUC, 0.709), and we were able to signiﬁcantly in-
crease the predictive performance of EGFR mutation. These ﬁnd-
ings suggested that the combination of radiomic data and
demographic information in a system model is more effective.
There are some limitations in this study. One limitation is that this
study is retrospective and limited to only Eastern Asian populations;
care should be taken before generalizing our ﬁndings to other pop-
ulations. Second, radiomic features were derived from semi-automatic
segmentation by radiologists, which can be inﬂuenced by observers’
subjective trend. However, the results of automatic boundary
extraction method were not satisfactory for all the lesions, particularly
in the case of tumors with GGO components, as their margins are
usually unclear from the adjacent normal lung parenchyma.
Furthermore, since atelectasis is common in patients with central lung
cancers, and differentiation between them is rather difﬁcult as both
appear as solid density onCT, our analysis did not include central lung
cancers. A prospective multi-Institutional study with a large patient
cohort would be required to conﬁrm our observations.Conclusion
In summary, this study revealed associations between CT based
radiomic features and EGFR mutation status in peripheral lungadenocarcinomas, and therefore non-invasive radiomic phenotype
analysis has the potential to improve the differentiation of EGFR
mutate from wild type when used in addition to clinical
predictors.
Clinical Practice Points
 The presence of activating EGFR mutations has been shown to
be prognostic for a more favorable outcome to TKI therapy in
lung adenocarcinomas.
 Several reports have described the relationship between muta-
tion status of EGFR and traditional radiological features.
Radiomic-based approach allows high throughput extraction of
quantitative parameters from CT images which beyond what is
visually perceived by the human eyes. Thus, we hypothesized
that radiomic analysis of routinely performed preoperative CT
images could provide imaging biomarkers for EGFR
mutations.
 In this study we demonstrated that eleven CT based radiomic
features have signiﬁcant association with EGFR mutations.
Adding radiomic features to clinical model could improve the
predicting power of EGFR mutations, thus helping in
formulating a better clinical decision without adding additional
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Supplemental Table 1 Quantitative Radiomic Features
Feature Category
Feature
Index Description of the Features
C1. Tumor Size F1 Longest diameter, mm
F 2 ShortAx-LongDia
F 3 Short axis, mm
F 6 Vol-cm3
F 33 Area-Pxl
F 34 Volume-Pxl
F 35 Num-Pxl
F 36 Width-Pxl
F 37 Thickness-Pxl
F 38 Length-Pxl
F 39 Length-by-Thick
F 40 Length-by-Width
F 41 Border-Leng-Pxl
C2. Tumor Shape
(Roundness)
F 7 5a-3D-MacSpic
F 13 9b-3D-Circularity
F 14 9c-3D-Compactness
F 23 Asymmetry
F 24 Compactness
F 26 Elliptic Fit
F 28 Radius of largest enclosed ellipse
F 29 Radius of smallest enclosed ellipse
F 30 Shape-Index
F 31 Roundness
F 32 Rectangular ﬁt
C3. Tumor Location F 8 8a-3D-Attch-Pleural wall
F 9 8b-3D-Border-to-Lung
F 10 8c-3D-Border-to-Pleural wall
F 11 8d-3D-Ratio-Free-to-Attach
F 12 9a-3D-FractionalAnisotropy
F 15 9d-3D-AV-Dist-COG-to-Border
F 16 9e-3D-SD-Dist-COG-to-Border
F 17 9f-3D-Min-Dist-COG-to-Border
F 18 9g-3D-Max-Dist-COG-to-Border
F 27 Main Direction
C4. Airspace F 19 10a_3D_Relative_Volume_AirSpaces
F 20 10b_3D_Number_AirSpaces
F 21 10c_3D_Av_Volume_AirSpaces
F 22 10d_3D_SD_Volume_AirSpaces
C5. Pixel Intensity
Histogram
F 4 Mean, Hounsﬁeld Units
F 5 StdDev [HU]
F 184 Histogram-Mean-Layer 1
F 185 Histogram-SD-Layer 1
F 186 Histogram-Energy-Layer 1
F 187 Histogram-Entropy-Layer 1
F 188 Histogram-Kurt-Layer 1
F 189 Histogram-Skew-Layer 1
F 25 Density
C6. Run Length and
Co-occurrence
F 42 AvgCoocurrence-Homo
F 43 AvgCoocurrence-Mp
F 44 AvgCoocurrence-Constrast
Supplemental Table 1 Continued
Feature Category
Feature
Index Description of the Features
F 45 AvgCoocurrence-Energy
F 46 AvgCoocurrence-Entropy
F 47 AvgCoocurrence-Mean
F 48 AvgGLN
F 49 AvgHGRE
F 50 AvgLGRE
F 51 AvgLRE
F 52 AvgLRHGE
F 53 AvgLRLGE
F 54 AvgRLN
F 55 AvgRP
F 56 AvgSRE
F 57 AvgSRHGE
F 58 AvgSRLGE
C7. Laws Texture
Feature (With Different
Convolution Filters)
F 59 3-D Laws features E5 E5 E5 Layer 1
F 60 3-D Laws features E5 E5 L5 Layer 1
F 61 3-D Laws features E5 E5 R5 Layer 1
F 62 3-D Laws features E5 E5 S5 Layer 1
F 63 3-D Laws features E5 E5 W5 Layer 1
F 64 3-D Laws features E5 L5 E5 Layer 1
F 65 3-D Laws features E5 L5 L5 Layer 1
F 66 3-D Laws features E5 L5 R5 Layer 1
F 67 3-D Laws features E5 L5 S5 Layer 1
F 68 3-D Laws features E5 L5 W5 Layer 1
F 69 3-D Laws features E5 R5 E5 Layer 1
F 70 3-D Laws features E5 R5 L5 Layer 1
F 71 3-D Laws features E5 R5 R5 Layer 1
F 72 3-D Laws features E5 R5 S5 Layer 1
F 73 3-D Laws features E5 R5 W5 Layer 1
F 74 3-D Laws features E5 S5 E5 Layer 1
F 75 3-D Laws features E5 S5 L5 Layer 1
F 76 3-D Laws features E5 S5 R5 Layer 1
F 77 3-D Laws features E5 S5 S5 Layer 1
F 78 3-D Laws features E5 S5 W5 Layer 1
F 79 3-D Laws features E5 W5 E5 Layer 1
F 80 3-D Laws features E5 W5 L5 Layer 1
F 81 3-D Laws features E5 W5 R5 Layer 1
F 82 3-D Laws features E5 W5 S5 Layer 1
F 83 3-D Laws features E5 W5 W5 Layer 1
F 84 3-D Laws features L5 E5 E5 Layer 1
F 85 3-D Laws features L5 E5 L5 Layer 1
F 86 3-D Laws features L5 E5 R5 Layer 1
F 87 3-D Laws features L5 E5 S5 Layer 1
F 88 3-D Laws features L5 E5 W5 Layer 1
F 89 3-D Laws features L5 L5 E5 Layer 1
F 90 3-D Laws features L5 L5 L5 Layer 1
F 91 3-D Laws features L5 L5 R5 Layer 1
F 92 3-D Laws features L5 L5 S5 Layer 1
F 93 3-D Laws features L5 L5 W5 Layer 1
F 94 3-D Laws features L5 R5 E5 Layer 1
F 95 3-D Laws features L5 R5 L5 Layer 1
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Supplemental Table 1 Continued
Feature Category
Feature
Index Description of the Features
F 96 3-D Laws features L5 R5 R5 Layer 1
F 97 3-D Laws features L5 R5 S5 Layer 1
F 98 3-D Laws features L5 R5 W5 Layer 1
F 99 3-D Laws features L5 S5 E5 Layer 1
F 100 3-D Laws features L5 S5 L5 Layer 1
F 101 3-D Laws features L5 S5 R5 Layer 1
F 102 3-D Laws features L5 S5 S5 Layer 1
F 103 3-D Laws features L5 S5 W5 Layer 1
F 104 3-D Laws features L5 W5 E5 Layer 1
F 105 3-D Laws features L5 W5 L5 Layer 1
F 106 3-D Laws features L5 W5 R5 Layer 1
F 107 3-D Laws features L5 W5 S5 Layer 1
F 108 3-D Laws features L5 W5 W5 Layer 1
F 109 3-D Laws features R5 E5 E5 Layer 1
F 110 3-D Laws features R5 E5 L5 Layer 1
F 111 3-D Laws features R5 E5 R5 Layer 1
F 112 3-D Laws features R5 E5 S5 Layer 1
F 113 3-D Laws features R5 E5 W5 Layer 1
F 114 3-D Laws features R5 L5 E5 Layer 1
F 115 3-D Laws features R5 L5 L5 Layer 1
F 116 3-D Laws features R5 L5 R5 Layer 1
F 117 3-D Laws features R5 L5 S5 Layer 1
F 118 3-D Laws features R5 L5 W5 Layer 1
F 119 3-D Laws features R5 R5 E5 Layer 1
F 120 3-D Laws features R5 R5 L5 Layer 1
F 121 3-D Laws features R5 R5 R5 Layer 1
F 122 3-D Laws features R5 R5 S5 Layer 1
F 123 3-D Laws features R5 R5 W5 Layer 1
F 124 3-D Laws features R5 S5 E5 Layer 1
F 125 3-D Laws features R5 S5 L5 Layer 1
F 126 3-D Laws features R5 S5 R5 Layer 1
F 127 3-D Laws features R5 S5 S5 Layer 1
F 128 3-D Laws features R5 S5 W5 Layer 1
F 129 3-D Laws features R5 W5 E5 Layer 1
F 130 3-D Laws features R5 W5 L5 Layer 1
F 131 3-D Laws features R5 W5 R5 Layer 1
F 132 3-D Laws features R5 W5 S5 Layer 1
F 133 3-D Laws features R5 W5 W5 Layer 1
F 134 3-D Laws features S5 E5 E5 Layer 1
F 135 3-D Laws features S5 E5 L5 Layer 1
F 136 3-D Laws features S5 E5 R5 Layer 1
F 137 3-D Laws features S5 E5 S5 Layer 1
F 138 3-D Laws features S5 E5 W5 Layer 1
F 139 3-D Laws features S5 L5 E5 Layer 1
F 140 3-D Laws features S5 L5 L5 Layer 1
F 141 3-D Laws features S5 L5 R5 Layer 1
F 142 3-D Laws features S5 L5 S5 Layer 1
F 143 3-D Laws features S5 L5 W5 Layer 1
F 144 3-D Laws features S5 R5 E5 Layer 1
F 145 3-D Laws features S5 R5 L5 Layer 1
F 146 3-D Laws features S5 R5 R5 Layer 1
F 147 3-D Laws features S5 R5 S5 Layer 1
Supplemental Table 1 Continued
Feature Category
Feature
Index Description of the Features
F 148 3-D Laws features S5 R5 W5 Layer 1
F 149 3-D Laws features S5 S5 E5 Layer 1
F 150 3-D Laws features S5 S5 L5 Layer 1
F 151 3-D Laws features S5 S5 R5 Layer 1
F 152 3-D Laws features S5 S5 S5 Layer 1
F 153 3-D Laws features S5 S5 W5 Layer 1
F 154 3-D Laws features S5 W5 E5 Layer 1
F 155 3-D Laws features S5 W5 L5 Layer 1
F 156 3-D Laws features S5 W5 R5 Layer 1
F 157 3-D Laws features S5 W5 S5 Layer 1
F 158 3-D Laws features S5 W5 W5 Layer 1
F 159 3-D Laws features W5 E5 E5 Layer 1
F 160 3-D Laws features W5 E5 L5 Layer 1
F 161 3-D Laws features W5 E5 R5 Layer 1
F 162 3-D Laws features W5 E5 S5 Layer 1
F 163 3-D Laws features W5 E5 W5 Layer 1
F 164 3-D Laws features W5 L5 E5 Layer 1
F 165 3-D Laws features W5 L5 L5 Layer 1
F 166 3-D Laws features W5 L5 R5 Layer 1
F 167 3-D Laws features W5 L5 S5 Layer 1
F 168 3-D Laws features W5 L5 W5 Layer 1
F 169 3-D Laws features W5 R5 E5 Layer 1
F 170 3-D Laws features W5 R5 L5 Layer 1
F 171 3-D Laws features W5 R5 R5 Layer 1
F 172 3-D Laws features W5 R5 S5 Layer 1
F 173 3-D Laws features W5 S5 E5 Layer 1
F 174 3-D Laws features W5 S5 L5 Layer 1
F 175 3-D Laws features W5 R5 W5 Layer 1
F 176 3-D Laws features W5 S5 R5 Layer 1
F 177 3-D Laws features W5 S5 S5 Layer 1
F 178 3-D Laws features W5 S5 W5 Layer 1
F 179 3-D Laws features W5 W5 E5 Layer 1
F 180 3-D Laws features W5 W5 L5 Layer 1
F 181 3-D Laws features W5 W5 R5 Layer 1
F 182 3-D Laws features W5 W5 S5 Layer 1
F 183 3-D Laws features W5 W5 W5 Layer 1
C8. Wavelets Texture
(Feature At Different
Layers)
F 190 3-D Wavelet decomposition.
P2 L2 C9 Layer 1
F 191 3-D Wavelet decomposition.
P1 L2 C9 Layer 1
F 192 3-D Wavelet decomposition.
P2 L2 C10 Layer 1
F 193 3-D Wavelet decomposition.
P2 L2 C11 Layer 1
F 194 3-D Wavelet decomposition.
P2 L2 C12 Layer 1
F 195 3-D Wavelet decomposition.
P2 L2 C13 Layer 1
F 196 3-D Wavelet decomposition.
P2 L2 C14 Layer 1
F 197 3-D Wavelet decomposition.
P2 L2 C15 Layer 1
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Supplemental Table 2 Spectrum of Epidermal Growth Factor
Receptor Mutations
Mutation Type
Number of Patients
(n [ 137) Percentage
Single Mutation
E18 2 1.46
E19 64 46.72
E20 3 2.19
E21 67 48.91
Combined Mutation
E20, E21 1 0.73
Supplemental Table 1 Continued
Feature Category
Feature
Index Description of the Features
F 198 3-D Wavelet decomposition.
P2 L2 C1 Layer 1
F 199 3-D Wavelet decomposition.
P2 L2 C2 Layer 1
F 200 3-D Wavelet decomposition.
P2 L2 C3 Layer 1
F 201 3-D Wavelet decomposition.
P2 L2 C4 Layer 1
F 202 3-D Wavelet decomposition.
P2 L2 C5 Layer 1
F 203 3-D Wavelet decomposition.
P2 L2 C6 Layer 1
F 204 3-D Wavelet decomposition.
P2 L2 C7 Layer 1
F 205 3-D Wavelet decomposition.
P2 L2 C8 Layer 1
F 206 3-D Wavelet decomposition.
P1 L2 C11 Layer 1
F 207 3-D Wavelet decomposition.
P1 L2 C10 Layer 1
F 208 3-D Wavelet decomposition.
P1 L2 C12 Layer 1
F 209 3-D Wavelet decomposition.
P1 L2 C13 Layer 1
F 210 3-D Wavelet decomposition.
P1 L2 C14 Layer 1
F 211 3-D Wavelet decomposition.
P1 L2 C15 Layer 1
F 212 3-D Wavelet decomposition.
P1 L2 C1 Layer 1
F 213 3-D Wavelet decomposition.
P1 L2 C2 Layer 1
F 214 3-D Wavelet decomposition.
P1 L2 C3 Layer 1
F 215 3-D Wavelet decomposition.
P1 L2 C4 Layer 1
F 216 3-D Wavelet decomposition.
P1 L2 C5 Layer 1
F 217 3-D Wavelet decomposition.
P1 L2 C6 Layer 1
F 218 3-D Wavelet decomposition.
P1 L2 C7 Layer 1
F 219 3-D Wavelet decomposition.
P1 L2 C8 Layer 1
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Supplemental Table 3 Independent Radiomic Features Included in the Analysis
Independent Imaging Features
F1 F3 F4 F5 F7 F8 F9 F11 F12 F13
F16 F17 F19 F20 F21 F22 F25 F26 F27 F28
F32 F40 F42 F44 F47 F49 F50 F51 F61 F64
F65 F66 F70 F88 F90 F92 F97 F100 F101 F111
F113 F117 F140 F145 F146 F174 F185 F186 F189 F190
F191 F206 F208 F209 F212 F216 F217 F218 F219
Supplemental Table 4 Univariate Analysis for Radiomic Features That Predict Epidermal Growth Factor Receptor Mutation Status
Radiomic Feature
Odds Ratio
PPoint
95% CI
Lower Upper
F3
Short axis, mm 0.56 0.32 1 .051
F25
Density 0.11 0.01 1.03 .053
F1
Longest Diameter, mm 0.57 0.32 1.03 .063
F5
StdDev [HU] 1.57 0.97 2.54 .064
F145
3-D Laws features S5 R5 L5 Layer 1 0.66 0.43 1.03 .067
F9
8b-3-D-Border-to-Lung 1.53 0.95 2.46 .077
F146
3-D Laws features S5 R5 R5 Layer 1 0.67 0.44 1.04 .077
F70
3-D Laws features E5 R5 L5 Layer 1 0.74 0.53 1.04 .082
F49
AvgHGRE 0.6 0.34 1.07 .084
F66
3-D Laws features E5 L5 R5 Layer 1 0.74 0.53 1.04 .086
F4
Mean, Hounsﬁeld unit 0.88 0.75 1.02 .091
F12
9a-3-D-FractionalAnisotropy 1.48 0.89 2.46 .132
F13
9b_3-D_Circularity 1.86 0.81 4.28 .143
F92
3-D Laws features L5 L5 S5 Layer 1 0.73 0.48 1.12 .150
F189
Histogram SKEW Layer 1 1.16 0.94 1.43 .154
F218
3-D wavelet decomposition. P1 L2 C7 Layer 1 1.11 0.96 1.29 .156
F219
3-D wavelet decomposition. P1 L2 C8 Layer 1 1.1 0.96 1.26 .168
F117
3-D Laws features R5 L5 S5 Layer 1 0.75 0.49 1.14 .176
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Supplemental Table 4 Continued
Radiomic Feature
Odds Ratio
PPoint
95% CI
Lower Upper
F65
3-D Laws features E5 L5 L5 Layer 1 0.8 0.57 1.12 .186
F50
AvgLGRE 0.73 0.45 1.18 .199
F101
3-D Laws features L5 S5 R5 Layer 1 0.77 0.51 1.16 .206
F8
8a-3-D-Attch-Pleural wall 0.75 0.48 1.19 .219
F216
3-D wavelet decomposition. P1 L2 C5 Layer 1 1.12 0.93 1.35 .219
F22
10d_3-D_SD_Volume_AirSpaces 1.06 0.96 1.18 .252
F217
3-D wavelet decomposition. P1 L2 C6 Layer 1 1.13 0.91 1.39 .268
F206
3-D wavelet decomposition. P1 L2 C11 Layer 1 1.18 0.86 1.62 .294
F97
3-D Laws features L5 R5 S5 Layer 1 0.79 0.51 1.24 .308
F209
3-D wavelet decomposition. P1 L2 C13 Layer 1 1.15 0.88 1.51 .318
F40
Length-by-Width 0.54 0.16 1.86 .330
F21
10c_3-D_Av_Volume_AirSpaces 1.06 0.95 1.18 .333
F191
3-D wavelet decomposition. P1 L2 C9 Layer 1 1.15 0.85 1.55 .363
F28
Radius of largest enclosed ellipse 1.18 0.79 1.77 .412
F140
3-D Laws features S5 L5 L5 Layer 1 0.85 0.56 1.27 .419
F20
10b_3-D_Number_AirSpaces 1.08 0.9 1.3 .424
F113
3-D Laws features R5 E5 W5 Layer 1 0.85 0.55 1.31 .460
F212
3-D wavelet decomposition. P1 L2 C1 Layer 1 0.92 0.71 1.2 .525
F100
3-D Laws features L5 S5 L5 Layer 1 0.9 0.59 1.35 .605
F44
AvgCoocurrence-contrast 0.9 0.56 1.44 .650
F32
Rectangular Fit 0.59 0.06 6.07 .655
F11
8d-3-D-Ratio-Free-to-Attach 1.02 0.92 1.14 .677
F42
AvgCoocurrence-Homo 1.47 0.17 12.97 .727
F61
3-D Laws features E5 E5 R5 Layer 1 0.94 0.6 1.45 .763
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Supplemental Table 4 Continued
Radiomic Feature
Odds Ratio
PPoint
95% CI
Lower Upper
F16
9e-3-D-SD-Dist-COG-to-Border 0.94 0.55 1.58 .803
F7
5a-3-D-MacSpic 1.18 0.29 4.81 .817
F64
3-D Laws features E5 L5 E5 Layer 1 0.95 0.62 1.48 .834
F208
3-D wavelet decomposition. P1 L2 C12 Layer 1 1.03 0.79 1.33 .848
F174
3-D Laws features W5 S5 L5 Layer 1 1.04 0.68 1.6 .863
F88
3-D Laws features L5 E5 W5 Layer 1 0.99 0.65 1.52 .976
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